Overview
This study is designed to assess safety, tolerability, pharmacokinetics (PK), formulation (liquid and solid oral forms) and food effect of ABI-H3733 in healthy participants. Part 1 includes evaluation of the safety, tolerability, and PK of ABI-H3733 during single ascending dose (SAD) and multiple-ascending dose (MAD) administration of the oral liquid formulation. Part 2 includes assessment of a solid dosage formulation of ABI-H3733 in participants under fasted conditions or after a high-fat meal. Optional cohorts may be enrolled in Parts 1 and 2 of the study to explore additional dose levels, solid oral dosage formulations, or for cohort expansion.
Eligibility
Inclusion Criteria:
- No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory results at screening.
Exclusion Criteria:
- Positive test results for human immunodeficiency virus (HIV) or hepatitis B or C.
- History of or current persistent drug or alcohol abuse.